Deutsche Bank Initiates Enanta Pharmaceuticals At Buy

Analysts at Deutsche Bank initiated coverage on

with a Buy rating, according to sources. The target price for Enanta Pharmaceuticals is set to $42. Enanta Pharmaceuticals shares have dropped 9.92% over the past 52 weeks, while the S&P 500 index has surged 10.82% in the same period. Enanta Pharmaceuticals' shares closed at $31.05 on Thursday.